VET heads into the post-earnings session carrying a Q1 loss, rising short borrow costs, and a short position that has been steadily unwinding for weeks.
Vermilion reported Q1 2026 results today, posting revenue of CAD 487.9 million — up from CAD 454.9 million a year earlier — but recording a net loss of CAD 145.5 million, compared to net income of CAD 15.0 million in Q1 2025. The loss was driven by unrealized derivative losses, not operating deterioration, a distinction the market appears to be processing cautiously. Shares closed at CAD 18.56, up 0.9% on the day, and have recovered 3.8% on the week, modestly lagging peers CVE (+10.5%) and OVV (+7.9%) over the same period.
The most eye-catching data point this week is in the borrow market. Cost to borrow has doubled to 1.27%, the highest reading in at least a month — yet the context matters. At 1.27%, this is still a relatively modest borrowing rate for an energy exploration name. The jump likely reflects short-term demand for borrows around the earnings print rather than a structural shift in conviction. Availability remains ample: lending pool utilization has drifted lower, from a 52-week peak near 48.5% down to roughly 15.6%, suggesting the borrowing market for VET is far from stressed. New shorts face no meaningful squeeze pressure.
The short position itself tells a story of sustained retreat. Short interest has fallen nearly 30% over the past month, from roughly 7.8 million shares to 5.5 million, bringing it to 3.6% of the free float. That is a meaningful unwind. The move gathered pace in mid-April and has continued steadily through to this week. The ORTEX short score of 38.5 — down from a recent high near 39.4 — reflects that easing pressure. The data does not indicate an aggressive bear case being rebuilt.
Valuation is where Vermilion's story gets more interesting. EV/EBITDA is running at 3.5x, down roughly 11% over the past month, suggesting the stock has cheapened relative to earnings power even as shares held near flat. The P/E ratio has moved sharply — up from under 5x a month ago to just over 10x now — driven largely by earnings estimate revisions rather than a re-rating of the equity. The EV/EBIT factor score ranks in the 74th percentile, a constructive read on operational efficiency relative to peers. Price-to-book is sitting just below 1.0x.
On the institutional side, BlackRock is the largest holder at 8.9% and added modestly in its most recent filing. Columbia Management built its position meaningfully, adding 685,000 shares through March. Mackenzie Financial was the most aggressive buyer, picking up 1.8 million shares in the quarter. Those are active adds, not passive drift — though the most recent filings lag the current period, so it is unclear whether those buyers held through the April selloff and subsequent recovery. Recent insider activity has been limited to equity award grants; the only open-market transaction was a small VP sale worth roughly USD 79,000.
The Q1 transcript and full results are now public. Whether management's commentary on production guidance, hedging positions, and European gas exposure shifts the analyst community — which has been largely quiet on fresh ratings — will be worth tracking in the days ahead.
See the live data behind this article on ORTEX.
Open VET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
